Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) FCF Margin: 2016-2025

Historic FCF Margin for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to -57.96%.

  • Ultragenyx Pharmaceutical's FCF Margin fell 878.00% to -57.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -71.58%, marking a year-over-year increase of 1011.00%. This contributed to the annual value of -75.27% for FY2024, which is 4426.00% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's FCF Margin is -57.96%, which was up 12.66% from -66.36% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's FCF Margin's 5-year high stood at -48.62% during Q4 2024, with a 5-year trough of -187.28% in Q1 2022.
  • For the 3-year period, Ultragenyx Pharmaceutical's FCF Margin averaged around -96.99%, with its median value being -67.12% (2023).
  • Within the past 5 years, the most significant YoY rise in Ultragenyx Pharmaceutical's FCF Margin was 12,405bps (2021), while the steepest drop was 23,316bps (2021).
  • Ultragenyx Pharmaceutical's FCF Margin (Quarterly) stood at -84.41% in 2021, then crashed by 2,910bps to -113.51% in 2022, then spiked by 4,639bps to -67.12% in 2023, then spiked by 1,850bps to -48.62% in 2024, then plummeted by 878bps to -57.96% in 2025.
  • Its FCF Margin stands at -57.96% for Q3 2025, versus -66.36% for Q2 2025 and -120.64% for Q1 2025.